{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:14:54Z","timestamp":1773260094017,"version":"3.50.1"},"reference-count":37,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p>Selective estrogen receptor modulators (SERMs) have the ability to bind the estrogen receptor (ER) and are known to confer ER agonist or antagonist effects depending on the target tissue. A number of newer SERMs, including bazedoxifene, lasofoxifene and ospemifene, are currently under clinical development for the prevention and treatment of postmenopausal osteoporosis and for other indications. Although the possibility of developing a single agent that has all of the desired characteristics of an ideal SERM seems to be unlikely, progress in the clinical development of SERMs targeted to the ER suggests that these newer compounds may have attributes that represent an improvement relative to existing SERMs. A new approach to menopausal therapy is the tissue selective estrogen complex or the pairing of a selective estrogen receptor modulator with estrogens. Further investigation will help to clarify relative benefits\/risks of novel SERMs in development within specific indications.<\/jats:p>","DOI":"10.1590\/s0004-27302010000200016","type":"journal-article","created":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T09:03:59Z","timestamp":1273741439000},"page":"200-205","source":"Crossref","is-referenced-by-count":19,"title":["SERMs in the prevention and treatment of postmenopausal osteoporosis: an update"],"prefix":"10.1590","volume":"54","author":[{"given":"Jaime","family":"Kulak J\u00fanior","sequence":"first","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Aguiar Moreira","family":"Kulak","sequence":"additional","affiliation":[{"name":"UFPR, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugh S.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulators \" Mechanisms of action and application to clinical practice","volume":"348","author":"Riggs BL","year":"2003","journal-title":"N Engl J Med."},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1091\/mbc.E03-06-0360","article-title":"Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta","volume":"15","author":"Kian Tee M","year":"2004","journal-title":"Mol Biol Cell."},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1258\/175404507780456791","article-title":"The future of the new selective estrogen receptor modulators","volume":"13","author":"Palacios S.","year":"2007","journal-title":"Menopause Int."},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1210\/er.2003-0023","article-title":"Coregulator function: a key to understanding tissue specificity of selective receptor modulators","volume":"25","author":"Smith CL","year":"2004","journal-title":"Endocr Rev."},{"issue":"19","key":"ref5","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/jnci\/93.19.1449","article-title":"Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease","volume":"93","author":"Jordan VC","year":"2001","journal-title":"J Natl Cancer Inst."},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14","volume":"86","author":"Fisher B","year":"1994","journal-title":"J Natl Cancer Inst."},{"issue":"13","key":"ref7","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love RR","year":"1992","journal-title":"N Engl J Med."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1196\/annals.1365.034","article-title":"The cardiovascular effects of selective estrogen receptor modulators","volume":"1092","author":"Christodoulakos GE","year":"2006","journal-title":"Ann N Y Acad Sci."},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.1991.9.2.286","article-title":"Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer","volume":"9","author":"Saphner T","year":"1991","journal-title":"J Clin Oncol."},{"issue":"9206","key":"ref10","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(05)72466-1","article-title":"Occurrence of stroke with tamoxifen in NSABP B-24","volume":"355","author":"Dignam JJ","year":"2000","journal-title":"Lancet."},{"issue":"23","key":"ref11","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas PD","year":"1997","journal-title":"N Engl J Med."},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger B","year":"1999","journal-title":"JAMA."},{"issue":"23","key":"ref13","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel VG","year":"2006","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial","volume":"87","author":"Delmas PD","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","article-title":"Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial","volume":"33","author":"Delmas PD","year":"2003","journal-title":"Bone","ISSN":"https:\/\/id.crossref.org\/issn\/8756-3282","issn-type":"print"},{"issue":"9","key":"ref16","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study","volume":"20","author":"Siris ES","year":"2005","journal-title":"J Bone Miner Res."},{"issue":"23","key":"ref17","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings SR","year":"1999","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"issue":"3 Pt 1","key":"ref18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/GME.0b013e318031a83d","article-title":"The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety","volume":"14","author":"Stovall DW","year":"2007","journal-title":"Menopause","ISSN":"https:\/\/id.crossref.org\/issn\/1072-3714","issn-type":"print"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0378-5122(99)00090-0","article-title":"Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials","volume":"34","author":"Cohen FJ","year":"2000","journal-title":"Maturitas","ISSN":"https:\/\/id.crossref.org\/issn\/0378-5122","issn-type":"print"},{"issue":"4","key":"ref20","first-page":"558","article-title":"Adverse events reported by postmenopausal women in controlled trials with raloxifene","volume":"93","author":"Davies GC","year":"1999","journal-title":"Obstet Gynecol."},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.7863\/jum.1999.18.7.503","article-title":"Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene","volume":"18","author":"Fleischer AC","year":"1999","journal-title":"J Ultrasound Med."},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0378-5122(02)00342-0","article-title":"Adverse effects of a SERM (Levormeloxifene): Safety parameters and bone mineral density 12 months after treatment withdrawal","volume":"44","author":"Warming L","year":"2003","journal-title":"Maturitas","ISSN":"https:\/\/id.crossref.org\/issn\/0378-5122","issn-type":"print"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene","volume":"13","author":"McClung MR","year":"2006","journal-title":"Menopause","ISSN":"https:\/\/id.crossref.org\/issn\/1072-3714","issn-type":"print"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00774-006-0689-9","article-title":"Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women","volume":"24","author":"Komi J","year":"2006","journal-title":"J Bone Miner Metab."},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09513590410001672197","article-title":"Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women","volume":"18","author":"Komi J","year":"2004","journal-title":"Gynecol Endocrinol."},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00042192-200512020-00015","article-title":"Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women","volume":"12","author":"Komi J","year":"2005","journal-title":"Menopause","ISSN":"https:\/\/id.crossref.org\/issn\/1072-3714","issn-type":"print"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial","volume":"10","author":"Rutanen EM","year":"2003","journal-title":"Menopause","ISSN":"https:\/\/id.crossref.org\/issn\/1072-3714","issn-type":"print"},{"issue":"16","key":"ref28","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1158\/1078-0432.CCR-04-0171","article-title":"Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator","volume":"10","author":"Fabian CJ","year":"2004","journal-title":"Clin Cancer Res."},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2008-2143","article-title":"Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass","volume":"94","author":"Bolognese M","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"ref30","series-title":"Lilly Reperts on outcome of Phase III of Arzoxifene, press release","author":"Company ELa","year":"2009"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1749-6632.2001.tb04039.x","article-title":"Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation","volume":"949","author":"Komm BS","year":"2001","journal-title":"Ann N Y Acad Sci."},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/01.AOG.0000163253.27610.b9","article-title":"Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women","volume":"105","author":"Ronkin S","year":"2005","journal-title":"Obstet Gynecol."},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller PD","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman SL","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.fertnstert.2009.05.093","article-title":"Bazedoxifene\/conjugated estrogens (BZA\/CE): incidence of uterine bleeding in postmenopausal women","volume":"92","author":"Archer DF","year":"2009","journal-title":"Fertil Steril."},{"key":"ref36","series-title":"Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women","author":"Archer DF","year":"2009"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay R","year":"2009","journal-title":"Fertil Steril."}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v54n2\/16.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:34:37Z","timestamp":1559104477000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302010000200016&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0004-27302010000200016"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302010000200016","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}